Antibiotic Management of Abdominal Abscesses

Risk Stratification & Source Control

• The choice of antibiotic regimen must consider three key factors: the patient’s immune status, severity of illness, and adequacy of source control (drainage or surgical intervention)【1】.

First‑Line Antibiotic Regimens

Non‑Critically Ill, Immunocompetent Patients with Adequate Drainage

• Amoxicillin‑clavulanate 2 g/0.2 g IV every 8 h for 4 days is recommended as the primary regimen when source control is adequate【1】.

Critically Ill or Immunocompromised Patients with Adequate Drainage

• Piperacillin‑tazobactam: loading dose 6 g/0.75 g, then 4 g/0.5 g IV every 6 h (or 16 g/2 g continuous infusion) is the preferred first‑line therapy【1】.
• Eravacycline 1 mg/kg IV every 12 h is an acceptable alternative for patients unable to receive β‑lactams【1】.

Patients with Inadequate/Delayed Source Control or ESBL Risk

• Ertapenem 1 g IV daily is recommended as the first‑line carbapenem when drainage is suboptimal or ESBL‑producing organisms are suspected【1】.
• Eravacycline 1 mg/kg IV every 12 h may be used as an alternative carbapenem‑sparing option【1】.

Septic Shock

• Meropenem 1 g IV every 6 h administered by extended or continuous infusion provides broad‑spectrum coverage with enhanced gram‑negative activity【1】.
• Alternatives include doripenem 500 mg q8 h (extended infusion), imipenem‑cilastatin 500 mg q6 h (extended infusion), or eravacycline 1 mg/kg q12 h【1】.
• Extended or continuous infusion optimizes time‑dependent β‑lactam pharmacodynamics in critically ill patients with augmented renal clearance【1】.

Documented or Suspected Multidrug‑Resistant (MDR) Pathogens

• Imipenem‑cilastatin‑relebactam 1.25 g IV every 6 h (extended infusion) is recommended for confirmed MDR infections【1】.
• Alternatives: meropenem‑vaborbactam 2 g/2 g q8 h or ceftazidime‑avibactam 2.5 g q8 h (both with extended/continuous infusion) plus metronidazole 500 mg q8 h【1】.

Duration of Therapy

• Four days of antimicrobial therapy is sufficient when source control is adequate and the patient is immunocompetent and non‑critically ill【1】.
• Seven days is advised for immunocompromised or critically ill patients, with the exact length guided by clinical improvement and trends in inflammatory markers (e.g., CRP, procalcitonin)【1】.
• Persistent fever or systemic illness beyond 7 days warrants repeat imaging and multidisciplinary reassessment to evaluate for inadequate drainage or alternative diagnoses【1】.
• Recent data demonstrate that a 4‑day course yields outcomes equivalent to longer regimens when definitive source control is achieved, while reducing overall antibiotic exposure and resistance risk【1】.

Antifungal Considerations

• Add antifungal therapy (fluconazole or an echinocandin) for immunosuppressed patients or when a candidal abscess is documented【1】.

Monitoring & Stewardship

• Do not extend antibiotic therapy beyond 7 days without reassessing source control; ongoing symptoms more often reflect inadequate drainage rather than treatment failure【1】.

All recommendations are based on the World Journal of Emergency Surgery (2024) guidelines and reflect the highest level of evidence available in the cited source.